Short Interest in Jaguar Health, Inc. (NASDAQ:JAGX) Expands By 138.4%

Jaguar Health, Inc. (NASDAQ:JAGX) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 332,300 shares, an increase of 138.4% from the October 15th total of 139,400 shares. Approximately 4.3% of the company’s stock are sold short. Based on an average daily trading volume, of 312,000 shares, the days-to-cover ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Jaguar Health from a “sell” rating to a “hold” rating in a research report on Friday, September 13th.

Hedge Funds Weigh In On Jaguar Health

A hedge fund recently bought a new stake in Jaguar Health stock. Perritt Capital Management Inc acquired a new stake in shares of Jaguar Health, Inc. (NASDAQ:JAGX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 25,000 shares of the biotechnology company’s stock, valued at approximately $90,000. Perritt Capital Management Inc owned 0.51% of Jaguar Health at the end of the most recent quarter. 12.04% of the stock is owned by hedge funds and other institutional investors.

Jaguar Health Price Performance

Shares of Jaguar Health stock traded down $0.08 during midday trading on Friday, hitting $0.96. The company had a trading volume of 220,630 shares, compared to its average volume of 742,778. The company has a debt-to-equity ratio of 1.32, a quick ratio of 1.60 and a current ratio of 2.10. The company has a fifty day simple moving average of $1.14 and a 200 day simple moving average of $3.75. Jaguar Health has a 12-month low of $0.90 and a 12-month high of $30.86.

Jaguar Health (NASDAQ:JAGX) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($4.04) EPS for the quarter, missing the consensus estimate of ($1.20) by ($2.84). The company had revenue of $2.72 million during the quarter. Jaguar Health had a negative net margin of 360.13% and a negative return on equity of 341.34%. As a group, analysts predict that Jaguar Health will post -0.78 earnings per share for the current fiscal year.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.